Jade Biosciences (JBIO) announced the appointment of Brad Dahms as Chief Financial Officer, CFO. Dahms was most recently Chief Financial Officer and Chief Business Officer of IDRx, a clinical-stage oncology company, where he led financial operations, investor relations, and business development, including its transition to a public-ready company and sale to GSK for up to $1.15 billion.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JBIO:
- Jade Biosciences upgraded to Buy from Neutral at Guggenheim
- Jade Biosciences presents JADE101 preclinical data at ERA Congress
- Is AVTE a Buy, Before Earnings?
- Promising Future for Jade Biosciences: Buy Rating Backed by Innovative JADE101 and Experienced Leadership
- Jade Biosciences Updates Corporate Presentation